Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 400 of the 401 references it cites were found in a registry or an index, and 1 are not checked yet; 69 of the 304 sources its claims cite were checked for support.

American Society of Hematology 2020 Guidelines for Management of Venous Thromboembolism: Treatment of Deep Vein Thrombosis and Pulmonary Embolism

Open access

Abstract

In August 2022, these guidelines were reviewed by an expert work group convened by ASH. Review included limited searches for new evidence and discussion of the search results. Following this review, the ASH Committee on Quality agreed to continue monitoring the supporting evidence rather than revise or retire these guidelines at this time. Limited searches and expert review will be repeated annually going forward until these guidelines are revised or retired. Background: Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), occurs in ∼1 to 2 individuals per 1000 each year, corresponding to ∼300 000 to 600 000 events in the United States annually. Objective: These evidence-based guidelines from the American Society of Hematology (ASH) intend to support patients, clinicians, and others in decisions about treatment of VTE. Methods: ASH formed a multidisciplinary guideline panel balanced to minimize potential bias from conflicts of interest. The McMaster University GRADE Centre supported the guideline development process, including updating or performing systematic evidence reviews. The panel prioritized clinical questions and outcomes according to their importance for clinicians and adult patients. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess evidence and make recommendations, which were subject to public comment. Results: The panel agreed on 28 recommendations for the initial management of VTE, primary treatment, secondary prevention, and treatment of recurrent VTE events. Conclusions: Strong recommendations include the use of thrombolytic therapy for patients with PE and hemodynamic compromise, use of an international normalized ratio (INR) range of 2.0 to 3.0 over a lower INR range for patients with VTE who use a vitamin K antagonist (VKA) for secondary prevention, and use of indefinite anticoagulation for patients with recurrent unprovoked VTE. Conditional recommendations include the preference for home treatment over hospital-based treatment for uncomplicated DVT and PE at low risk for complications and a preference for direct oral anticoagulants over VKA for primary treatment of VTE.

Verified 2026-10-05 · 1 reference not checked yet

Overview

CoChat Summary

TL;DR

These ASH 2020 guidelines provide 28 GRADE-based recommendations for treatment of DVT and PE in patients without cancer, covering initial management, primary treatment, secondary prevention, recurrent events, and additional management issues. Strong recommendations include thrombolysis for PE with hemodynamic compromise, INR 2.0-3.0 over a lower INR range for VKA secondary prevention, and indefinite anticoagulation for recurrent unprovoked VTE.

Key findings

  • The panel agreed on 28 recommendations. Strong recommendations include thrombolytic therapy for PE with hemodynamic compromise, INR range 2.0-3.0 over lower INR for VTE patients on a VKA for secondary prevention, and indefinite anticoagulation for recurrent unprovoked VTE. Conditional recommendations include home treatment over hospital treatment for uncomplicated DVT and low-risk PE, and DOACs over VKAs for primary treatment of VTE.
  • DOAC vs VKA: major bleeding was reduced with DOACs (RR, 0.63; 95% CI, 0.47-0.84; ARR, 6 fewer per 1000 patients; high-certainty evidence), with no impact on mortality (RR, 0.99; 95% CI, 0.85-1.15) or PE (RR, 0.97; 95% CI, 0.77-1.23), and a non-significant reduction in DVT (RR, 0.80; 95% CI, 0.59-1.09).
  • Home vs hospital for DVT: home treatment reduced PE (RR, 0.64; 95% CI, 0.44-0.93; ARR, 25 fewer per 1000 patients) and subsequent DVT (RR, 0.61; 95% CI, 0.42-0.90; ARR, 29 fewer per 1000 patients), with lower major bleeding (RR, 0.67; 95% CI, 0.33-1.36; low-certainty evidence).
  • Thrombolysis for PE with hemodynamic compromise may reduce mortality (RR, 0.61; 95% CI, 0.40-0.94; ARR, 58 fewer per 1000 patients; low-certainty evidence), but thrombolytics increased major bleeding (RR, 1.89; 95% CI, 1.46-2.46; ARR, 31 more per 1000 patients; high-certainty evidence) and intracranial bleeding (RR, 3.17; 95% CI, 1.19-8.41; ARR, 7 more per 1000 patients; moderate-certainty evidence).

Methods

  • ASH formed a multidisciplinary guideline panel balanced to minimize bias; the McMaster University GRADE Centre supported guideline development, including updating or performing systematic evidence reviews. The panel prioritized clinical questions and outcomes, used the GRADE approach and Evidence-to-Decision frameworks, and subjected recommendations to public comment.
  • Evidence synthesis included searches for systematic reviews on MEDLINE, Embase, the Cochrane Library, and Epistemonikos from inception to January 2017, updated to January 2019; the panel conducted its own meta-analyses using random-effects Mantel-Haenszel methods, explored heterogeneity with χ² and I², and used RevMan 5.3.
  • Outcomes rated critical across questions were mortality, PE, proximal DVT, and major bleeding; PTS was also rated critical for thrombolysis in DVT and compression stockings questions.

Limitations

  • The paper states that not all day-to-day challenges in VTE treatment are covered, that new evidence may change recommendations especially those based on low- or very-low-certainty evidence, and that the recommendations do not replace careful consideration of specific clinical circumstances and patients’ values and preferences.
  • The paper states and the text makes evident that many recommendations are conditional because of low or very low certainty; evidence limitations include imprecision, risk of bias (e.g., unblinded trials), indirectness, small event numbers, and lack of head-to-head DOAC comparisons.
  • The paper states the guidelines were developed primarily for North America, and resource considerations, feasibility, and acceptability may vary by region; cancer, high bleeding risk, renal/hepatic insufficiency, and antiphospholipid syndrome are noted as populations for which some recommendations may not apply or are addressed separately.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1182/bloodadvances.2020001830

Cites

400 of 401 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

47 Valid · 4 Not valid · 93 Not checked · 207 Own results and interpretations

236 more claims · 33 with their cited sources checked

Create a free account to see all 351 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 52
  • It may state two separate claims as one. 66
  • The quote only partly states this claim. 7

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 6 · the rest aren’t loaded

1 more finding

Create a free account to see every finding of this check.

See all findings — free account

Citations

Cites

Show all 392 references

Research works printed but not linked: 21

  1. 2012, J Clin Epidemiol
  2. 2020, Canadian Agency for Drugs and Technologies in Health. Rivaroxaban (Xarelto): treatment of venous thromboembolic events (deep vein thrombosis [DVT], pulmonary embolism [PE]) and prevention of recurrent DVT and PE.
  3. Jimenez, 2015, Cost-effectiveness of rivaroxaban in the treatment of venous thromboembolism in Spain, Pharmacoeconomics - Spanish Research Articles, 12, 147
  4. Jimenez, 2020, Efficacy of thrombolytic therapy in patients with massive pulmonary embolism: systematic review and meta-analysis, Am J Respir Crit Care Med, 201, A3783
  5. Liu, 2013, The effect of thrombolysis and anticoagulation therapy in patients with sub-massive pulmonary embolism [in Chinese]. Chongqing Med J, 42, 1288
  6. Ou, 2012, Analysis of the therapeutic effect of urokinase plus sequential anticoagulation for the treatment of sub-massive pulmonary embolism [in Chinese], J Hainan Medical College, 18, 897
  7. Sun, 2012, Efficacy of urokinase combined with low molecular weight heparin and warfarin for the treatment of sub-massive pulmonary embolism [in Chinese], Strait Pharmaceutical J, 24, 130
  8. Zhang, 2012, The effectiveness of low-dose rt-PA thrombolysis in 26 elderly patients with acute sub-massive pulmonary embolism [in Chinese], Shandong Yiyao, 52, 69
  9. Gong, 2005, Thrombolysis for the treatment of lower extremities deep vein thrombosis [in Chinese], J. Chinese Physician, 7, 1101
  10. Yu, 2009, Using interventional urokinase thrombolysis for the treatment of low extremities deep vein thrombosis [in Chinese], J Southern Medical University, 9, 1930
  11. Eichinger, 2013, D-dimer levels over time and the risk of recurrent venous thromboembolism: an update of the Vienna prediction model, J Thromb Haemost, 11, 115
  12. Lazo-Langner, 2013, The use of the REVERSE study clinical prediction rule for risk stratification after initial anticoagulation results in decreased recurrences in patients with idiopathic venous thromboembolism, J Thromb Haemost, 11, 879
  13. Marcucci, 2013, External validation and updating of the Vienna Prediction Model for recurrent venous thromboembolism using a pooled individual patient data database, J Thromb Haemost, 11, 879
  14. 2020, Clinical decision rule validation study to predict low recurrent risk in patients with unprovoked venous thromboembolism (REVERSEII). Identifier NCT00967304
  15. Raskob, 2011, Risk assessment for recurrent venous thromboembolism (VTE) after 6-14 months of anticoagulant treatment, J Thromb Haemost, 9, 857
  16. Rodger, 2013, The REVERSE I and II studies: impact of using. Men continue and HERDOO2 clinical decision rule to guide anticoagulant therapy in patients with first unprovoked venous thromboembolism, J Thromb Haemost, 11, 114
  17. Rodger, 2011, Extended follow-up of the multi-center prospective cohort that derived the ‘men continue and HERDOO2‘ clinical decision rule identifying low risk unprovoked patients, J ThrombHaemost, 9, 39
  18. Tosetto, 2010, Clinical prediction of VTE recurrence in patients with previous unprovoked venous thromboembolism. Results from an individual-level meta-analysis, Pathophysiol Haemost Thromb
  19. Tosetto, 2009, Clinical prediction guide to predict thrombosis recurrence after a first unprovoked venous thromboembolism, J Thromb Haemost
  20. 2020, Nederlands Trial Register. Cost-effectiveness of tailoring anticoagulant therapy by a VTE recurrence prediction model in patients with venous thrombo-embolism as compared to care-as-usual: The VISTA study. Trial NL2562 (NTR2680)
  21. Villalta, 1994, Assessment of validity and reproducibility of a clinical scale for the post-thrombotic syndrome [abstract], Haemostasis, 24, 158a

Cited by

See all 1,489

Metadata

Authors
Ortel, T. L., Neumann, I., Ageno, W., Beyth, R., Clark, N. P., Cuker, A., Hutten, B. A., Jaff, M. R., Manja, V., Schulman, S., Thurston, C., Vedantham, S., Verhamme, P., Witt, D. M., D. Florez, I., Izcovich, A., Nieuwlaat, R., Ross, S., J. Schünemann, H., Wiercioch, W., Zhang, Y., & Zhang, Y.
Affiliations
  • Duke University (US)
  • Pontificia Universidad Católica de Chile (CL)
  • University of Insubria (IT)
  • University of Florida Health (US)
  • Kaiser Permanente (US)
  • University of Pennsylvania (US)
  • Amsterdam University Medical Centers (NL)
  • Harvard University (US)
  • VA Northern California Health Care System (US)
  • Sechenov University (RU)
  • 14May-Thurner Syndrome Resource Network;
  • Washington University in St. Louis (US)
  • KU Leuven (BE)
  • University of Utah (US)
  • 18Department of Pediatrics, University of Antioquia, Medellin, Colombia;
  • Hospital Alemán (AR)
  • McMaster University (CA)
  • 19Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada;
Venue
Blood Advances
Published
2020-10-02
Volume
4
Issue
19
Pages
4693-4738
ISSN
  • 2473-9529 (ISSN-L)
  • 2473-9537
OpenAlex
W3090209681
Cited by
1,489
References
392
Citations by year
2026: 216 · 2025: 293 · 2024: 335 · 2023: 268 · 2022: 213 · 2021: 156 · 2020: 5
FWCI
91.13
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Blood Advances (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion, other-oa)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
  • Lirias (KU Leuven) (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
  • IrInSubria (University of Insubria) (submittedVersion)
  • Padua Research Archive (University of Padova) (submittedVersion)
Topics
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
  • Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
Keywords
venous thromboembolism, deep vein thrombosis, pulmonary embolism, anticoagulation, thrombolysis, vitamin K antagonists, direct oral anticoagulants, secondary prevention, recurrent venous thromboembolism, unprovoked venous thromboembolism, indefinite anticoagulation, home treatment, international normalized ratio
MeSH terms
Hematology, Humans, Pulmonary Embolism, United States, Evidence-Based Medicine, Venous Thrombosis, Venous Thromboembolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-01, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-01 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: American Society of Hematology 2020 Guidelines for Management of Venous Thromboembolism: Treatment of Deep Vein Thrombosis and Pulmonary Embolism. https://app.cochat.ai/papers/10.1182/bloodadvances.2020001830
The paper
Ortel, T. L., Neumann, I., Ageno, W., Beyth, R., Clark, N. P., Cuker, A., Hutten, B. A., Jaff, M. R., Manja, V., Schulman, S., Thurston, C., Vedantham, S., Verhamme, P., Witt, D. M., D. Florez, I., Izcovich, A., Nieuwlaat, R., Ross, S., J. Schünemann, H., . . . Zhang, Y. (2020). American Society of Hematology 2020 Guidelines for Management of Venous Thromboembolism: Treatment of Deep Vein Thrombosis and Pulmonary Embolism. Blood Advances. https://doi.org/10.1182/bloodadvances.2020001830

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.